MBCProject_0852_T2_RNA
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.570
- E2F_TARGETS+0.490
- MYC_TARGETS_V2+0.470
- G2M_CHECKPOINT+0.340
- OXIDATIVE_PHOSPHORYLATION+0.310
- MYOGENESIS+0.250
- ANGIOGENESIS+0.240
- COAGULATION+0.240
- SPERMATOGENESIS+0.240
- APICAL_JUNCTION+0.230
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.350
- ESTROGEN_RESPONSE_EARLY-0.310
- INTERFERON_ALPHA_RESPONSE-0.300
- APICAL_SURFACE-0.290
- INTERFERON_GAMMA_RESPONSE-0.230
- UV_RESPONSE_DN-0.230
- P53_PATHWAY-0.200
- HYPOXIA-0.190
- TGF_BETA_SIGNALING-0.190
- IL6_JAK_STAT3_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 88d93a8f-77d0-44e0-a58e-19f2c546afcf | — | — | 0.740 |
| 2 | TCGA-PQ-A6FN-01A-11R-A31N-07 | — | — | 0.739 |
| 3 | GSM5359432 | — | — | 0.729 |
| 4 | TCGA-AO-A12F-01A-11R-A115-07 | — | E | 0.727 |
| 5 | TCGA-B6-A0RU-01A-11R-A084-07 | — | E | 0.724 |
| 6 | MNG103 | — | — | 0.713 |
| 7 | TCGA-A2-A0T0-01A-22R-A084-07 | — | E | 0.710 |
| 8 | 79276 | EPN | Supratentorial EPN | 0.706 |
| 9 | 5a575c2e-b083-4897-87e5-4d2e823bf73f | — | — | 0.701 |
| 10 | MNG646 | — | — | 0.699 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |